Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
COLL | US
-0.15
-0.39%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
30/08/2024
38.46
38.51
38.64
37.93
Collegium Pharmaceutical Inc. a specialty pharmaceutical company develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily around-the-clock long-term opioid treatment; Nucynta ER and Nucynta IR which are extended-release and immediate-release formulations of tapentadol; Belbuca a buccal film that contains buprenorphine; and Symproic an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals Inc. and changed its name to Collegium Pharmaceutical Inc. in October 2003. Collegium Pharmaceutical Inc. was incorporated in 2002 and is headquartered in Stoughton Massachusetts.
View LessStrong Operating Margin (> 25%)
Strong Sharpe Ratio (> 1.2)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
30.9%1 month
44.7%3 months
40.3%6 months
43.3%13.98
5.55
5.53
2.58
0.53
4.15
2.58
-
347.36M
1.24B
1.24B
-
32.68
52.30
7.20
47.87
11.46
23.54
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
3.87
Range1M
5.64
Range3M
8.64
Rel. volume
0.48
Price X volume
7.66M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
OPKO Health Inc | OPK | Drug Manufacturers-Specialty & Generic | 1.68 | 1.17B | 5.66% | n/a | 19.31% |
Evolus Inc | EOLS | Drug Manufacturers-Specialty & Generic | 15.89 | 1.00B | 0.38% | n/a | 656.27% |
PetIQ Inc | PETQ | Drug Manufacturers-Specialty & Generic | 30.55 | 913.01M | 0.10% | 82.57 | 178.54% |
Phibro Animal Health Corporation | PAHC | Drug Manufacturers-Specialty & Generic | 21 | 850.58M | -2.19% | 324.33 | 204.74% |
Ironwood Pharmaceuticals Inc | IRWD | Drug Manufacturers-Specialty & Generic | 5.06 | 808.28M | -0.98% | 62.00 | -199.01% |
Pacira Pharmaceuticals Inc | PCRX | Drug Manufacturers-Specialty & Generic | 15.56 | 717.73M | 1.30% | 10.34 | 73.76% |
Canopy Growth Corporation | CGC | Drug Manufacturers-Specialty & Generic | 5.21 | 575.57M | 0.58% | n/a | 117.00% |
Radius Health Inc | RDUS | Drug Manufacturers-Specialty & Generic | 15.14 | 421.49M | 0.13% | n/a | 0.00% |
Aquestive Therapeutics Inc | AQST | Drug Manufacturers-Specialty & Generic | 4.53 | 412.50M | 2.95% | n/a | -329.45% |
Organogenesis Holdings Inc | ORGO | Drug Manufacturers-Specialty & Generic | 2.88 | 381.82M | -0.69% | n/a | 42.12% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Pitney Bowes Inc | PBI | Building Products & Equipment | 7.07 | 1.27B | 0.43% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.74 | 1.17B | -2.65% | n/a | 19.46% |
Interface Inc | TILE | Textile Manufacturing | 18.88 | 1.10B | 0.16% | 15.75 | 106.26% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 21.94 | 990.13M | 0.14% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 36.37 | 743.39M | 4.66% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.25 | 722.36M | 0.32% | 51.36 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 23.91 | 621.28M | 1.18% | 14.36 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.48 | 524.97M | 0.55% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 12.45 | 391.86M | -0.16% | 45.64 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 24.03 | 385.84M | 0.33% | n/a | 286.96% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 4.15 | - | Cheaper |
Ent. to Revenue | 2.58 | - | Cheaper |
PE Ratio | 13.98 | 28.13 | Cheaper |
Price to Book | 5.53 | 11.07 | Cheaper |
Dividend Yield | - | - | - |
Std. Deviation (3M) | 40.31 | - | Lower Risk |
Debt to Equity | 2.58 | -0.91 | Expensive |
Debt to Assets | 0.53 | 0.45 | Par |
Market Cap | 1.24B | - | Emerging |